VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

Stock Comparison

WuXi AppTec Co., Ltd. vs Pfizer Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

WuXi AppTec Co., Ltd.

603259 · Shanghai Stock Exchange

Market cap (USD)$37.4B
Gross margin (TTM)49.2%
Operating margin (TTM)42.7%
Net margin (TTM)41.7%
SectorHealthcare
IndustryMedical - Diagnostics & Research
CountryCN
Data as of2026-05-01
Moat score
72/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into WuXi AppTec Co., Ltd.'s moat claims, evidence, and risks.

View 603259 analysis

Pfizer Inc.

PFE · New York Stock Exchange

Market cap (USD)$149.2B
Gross margin (TTM)69.4%
Operating margin (TTM)23.5%
Net margin (TTM)11.8%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryUS
Data as of2025-12-29
Moat score
58/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Pfizer Inc.'s moat claims, evidence, and risks.

View PFE analysis

Comparison highlights

  • Moat score gap: WuXi AppTec Co., Ltd. leads (72 / 100 vs 58 / 100 for Pfizer Inc.).
  • Segment focus: WuXi AppTec Co., Ltd. has 3 segments (84% in WuXi Chemistry); Pfizer Inc. has 5 segments (47.4% in Primary Care).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Moderate vs Moderate.
  • Moat breadth: WuXi AppTec Co., Ltd. has 5 moat types across 3 domains; Pfizer Inc. has 8 across 3.

Primary market context

WuXi AppTec Co., Ltd.

WuXi Chemistry

Market

Global synthetic-molecule CRDMO services, including small-molecule discovery, process development, API manufacturing, peptides and oligonucleotides

Geography

Global, with major customer exposure to the United States, Europe and China

Customer

Large pharmaceutical companies, emerging biotechs and virtual pharma companies

Role

Integrated contract research, development and manufacturing partner across discovery, development and commercial manufacturing

Revenue share

84%

Pfizer Inc.

Primary Care

Market

Branded primary care medicines and vaccines (incl. cardiovascular, migraine, pneumococcal/RSV/COVID-19)

Geography

Global

Customer

Healthcare providers, payers/PBMs, pharmacies/wholesalers, and government procurement

Role

Innovator biopharma (R&D + manufacturing + commercialization)

Revenue share

47.4%

Side-by-side metrics

WuXi AppTec Co., Ltd.
Pfizer Inc.
Ticker / Exchange
603259 - Shanghai Stock Exchange
PFE - New York Stock Exchange
Market cap (USD)
$37.4B
$149.2B
Gross margin (TTM)
49.2%
69.4%
Operating margin (TTM)
42.7%
23.5%
Net margin (TTM)
41.7%
11.8%
Sector
Healthcare
Healthcare
Industry
Medical - Diagnostics & Research
Drug Manufacturers - General
HQ country
CN
US
Primary segment
WuXi Chemistry
Primary Care
Market structure
Competitive
Oligopoly
Market share
6%-9% (implied)
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
72 / 100
58 / 100
Moat domains
Supply, Demand, Legal
Legal, Demand, Supply
Last update
2026-05-01
2025-12-29

Moat coverage

Shared moat types

Compliance AdvantageOperational Excellence

WuXi AppTec Co., Ltd. strengths

Scope EconomiesDesign In QualificationCapacity Moat

Pfizer Inc. strengths

IP Choke PointProcurement InertiaGovernment Contracting RelationshipsCapex Knowhow ScaleLong Term ContractsEmbedded R&D partnership platform

Segment mix

WuXi AppTec Co., Ltd. segments

Full profile >

WuXi Chemistry

Competitive

84%

WuXi Testing

Competitive

9.3%

WuXi Biology

Competitive

6.2%

Pfizer Inc. segments

Full profile >

Primary Care

Oligopoly

47.4%

Specialty Care

Oligopoly

26.2%

Oncology

Competitive

24.5%

Pfizer CentreOne

Competitive

1.8%

Pfizer Ignite

Competitive

0.1%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.